SGLT2 inhibitors and chronic kidney disease: a narrative review of nephroprotective mechanisms from hemodynamics to metabolism

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, originally designed for the treatment of type 2 diabetes, have become a critical preventive therapy for chronic kidney disease (CKD). Moreover, they exhibit substantial reductions in the risk of kidney function deterioration, progression to end-stag...

Descripción completa

Detalles Bibliográficos

Autores principales:	Elmukhtar Habas, Amnna Rayani, Ala Habas, Khaled Alarbi, Aml Habas, Mohamed Baghi, Eshrak Habas, Elmehdi Errayes, Abdelrahaman Hamad, Abdelnaser Elzouki
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Taylor & Francis Group 2026-12-01
Colección:	Renal Failure
Materias:	SGLT2 inhibitors nephroprotection tubuloglomerular feedback renal hemodynamics NLRP3 inflammasome kidney fibrosis
Acceso en línea:	https://www.tandfonline.com/doi/10.1080/0886022X.2026.2688578
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!